Onvansertib - TrovaGene

Drug Profile

Onvansertib - TrovaGene

Alternative Names: NMS-1286937; NMS-P937; PCM 075

Latest Information Update: 31 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer TrovaGene
  • Class Antineoplastics; Piperazines; Pyrazoles; Quinazolines; Small molecules
  • Mechanism of Action Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Phase I/II Acute myeloid leukaemia
  • Phase I Solid tumours
  • Preclinical Breast cancer; Lung cancer; Non-Hodgkin's lymphoma

Most Recent Events

  • 07 Nov 2018 TrovaGene announces intention to submit IND application to the US FDA for Colorectal cancer (Metastatic disease) by end of 2018 (PO)
  • 07 Nov 2018 TrovaGene plans a phase I/II trial for Colorectal Cancer (Metastatic disease) in USA in H1 of 2019 (PO)
  • 24 Oct 2018 Trovagene was granted claims for patent application entitled "Nucleophosmin Protein (NPM) Mutants, Corresponding Gene Sequences and Uses Thereof" by the USPTO in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top